Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Obicetrapib safety analysis: Pooled phase 3 clinical trial experience.

American journal of preventive cardiology·2026
Same author

Cholesteryl ester transfer protein inhibition with obicetrapib is associated with attenuated decline in kidney function in patients at high cardiovascular risk: Post hoc pooled results from the BROADWAY and BROOKLYN trials.

American journal of preventive cardiology·2026
Same author

Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials.

European heart journal·2026
Same author

The emerging role of CETP inhibition in the prevention of Alzheimer's disease.

American journal of preventive cardiology·2026
Same author

Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.

Nature medicine·2026
Same author

Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.

Nature medicine·2026
Same journal

Vitamin K1 as a screening marker to facilitate the genetic diagnosis of class I familial hypobetalipoproteinemia: A prospective cohort study with a systematic review analysis.

Journal of clinical lipidology·2026
Same journal

Response to: Comment on "Plasma-based low-grade inflammation and endothelial dysfunction explain a small but significant proportion of the association between the n-3 polyunsaturated fatty acids and cardiovascular diseases: The Maastricht Study".

Journal of clinical lipidology·2026
Same journal

Response to letter regarding article, "Apolipoproteins, lipoprotein(a), and conventional markers of dyslipidemia in children with nephrotic syndrome in disease remission".

Journal of clinical lipidology·2026
Same journal

Apolipoprotein B reduction and coronary plaque delipidation: Clarifying treatment dynamics and analytic thresholds.

Journal of clinical lipidology·2026
Same journal

Recurrence of cardiovascular events despite achieving LDL-C <1.4 mmol/L in patients with coronary artery disease.

Journal of clinical lipidology·2026
Same journal

Association of small dense LDL cholesterol and inflammation with plaque rupture in acute coronary syndrome: An OCT study.

Journal of clinical lipidology·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

Optimized Negative Staining: a High-throughput Protocol for Examining Small and Asymmetric Protein Structure by Electron Microscopy
09:37

Optimized Negative Staining: a High-throughput Protocol for Examining Small and Asymmetric Protein Structure by Electron Microscopy

Published on: August 15, 2014

Update on CETP inhibition.

Michael H Davidson1

  • 1The University of Chicago Pritzker School of Medicine, 515 North State Street, Suite 2700, Chicago, IL 60654, USA. michaeldavidson@radiantresearch.com

Journal of Clinical Lipidology
|December 3, 2010
PubMed
Summary
This summary is machine-generated.

Cholesteryl ester transfer protein (CETP) inhibition may reduce atherosclerosis risk in dyslipidemia. While some CETP inhibitors show promise, further research is needed to confirm safety and efficacy, particularly regarding off-target effects.

More Related Videos

Functional Assessment of Kinesin-7 CENP-E in Spermatocytes Using In Vivo Inhibition, Immunofluorescence and Flow Cytometry
09:41

Functional Assessment of Kinesin-7 CENP-E in Spermatocytes Using In Vivo Inhibition, Immunofluorescence and Flow Cytometry

Published on: December 28, 2021

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

Related Experiment Videos

Last Updated: Jun 6, 2026

Optimized Negative Staining: a High-throughput Protocol for Examining Small and Asymmetric Protein Structure by Electron Microscopy
09:37

Optimized Negative Staining: a High-throughput Protocol for Examining Small and Asymmetric Protein Structure by Electron Microscopy

Published on: August 15, 2014

Functional Assessment of Kinesin-7 CENP-E in Spermatocytes Using In Vivo Inhibition, Immunofluorescence and Flow Cytometry
09:41

Functional Assessment of Kinesin-7 CENP-E in Spermatocytes Using In Vivo Inhibition, Immunofluorescence and Flow Cytometry

Published on: December 28, 2021

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

Area of Science:

  • Biochemistry
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Cholesteryl ester transfer protein (CETP) is crucial for reverse cholesterol transport and cholesterol homeostasis.
  • CETP activity, influenced by triglyceride (TG) levels, can promote atherogenic dyslipidemia by transferring cholesteryl esters to VLDL.
  • Combined actions of CETP and hepatic lipase with TG-rich lipoproteins generate small, dense HDL and LDL particles, contributing to atherosclerosis.

Purpose of the Study:

  • To evaluate the potential of CETP inhibition as a therapeutic strategy for reducing atherosclerosis in patients with dyslipidemia.
  • To assess the efficacy and safety of small-molecule CETP inhibitors, including dalcetrapib, torcetrapib, and anacetrapib.
  • To investigate the role of off-target effects, such as on the renin-angiotensin-aldosterone system (RAAS), in the clinical outcomes of CETP inhibitors.

Main Methods:

  • Review of preclinical and clinical studies on CETP inhibitors.
  • Analysis of lipid profiles and atherosclerosis progression in patients with dyslipidemia.
  • Examination of off-target effects of CETP inhibitors on the RAAS.

Main Results:

  • CETP inhibition has consistently reduced atherosclerosis in animal models.
  • Three CETP inhibitors (dalcetrapib, torcetrapib, anacetrapib) demonstrated beneficial effects on lipid profiles in clinical studies.
  • Torcetrapib's clinical development was halted due to off-target RAAS effects, while dalcetrapib shows preclinical promise for lacking these adverse effects.

Conclusions:

  • CETP inhibition remains a viable therapeutic strategy for atherosclerosis, provided the inhibitor lacks adverse off-target effects.
  • Further Phase 3 studies are required to confirm the safety and efficacy of dalcetrapib, particularly its lack of RAAS-related adverse effects.
  • Developing CETP inhibitors without the off-target effects seen with torcetrapib is crucial for successful clinical application.